How T cell genes and signals affect atherosclerosis
Official title: Influence of T cell genotype/phenotype in atherosclerotic cardiovascular disease
Funded at Ohio State University · NIH-11393308 · Data updated 2026-11-12
This grant studies how a specific immune cell and its signals influence atherosclerosis in people, aiming to uncover new ways to reduce inflammation and heart disease risk.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | June 1, 2023 |
| Project end | May 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $694,496 |
| NIH project number | 5R01HL167511-04 |
| Project ID | NIH-11393308 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults with ASCVD or at risk due to inflammatory or genetic factors related to CD39-regulated T cell function.
✕Less likely to help
People without ASCVD risk or immune-related factors involved in CD39 regulation may not experience direct benefit.
What this research studies
Researchers at Ohio State University are looking at a type of immune cell called regulatory T cells and a molecule called CD39 to understand how genetic differences can change inflammation in arteries. They will explore how changes in Treg function and purinergic signaling might drive or slow down atherosclerotic disease. The project uses human-relevant data and models to connect genetics, immune biology, and ASCVD outcomes. The work could point to new therapeutic approaches that modulate immune responses to prevent heart disease.
Why it matters
Potential benefit: If successful, the research could lead to novel immune-based strategies to prevent or treat ASCVD.
How similar studies have gone: Previous work has linked CD39 and Tregs to inflammation, with therapeutic strategies showing promise in related contexts, suggesting potential applicability here.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Gumina, Richard J — Ohio State University
- Study coordinator: Gumina, Richard J
Related research
Other NIH-funded projects on the same topics.
-
Integrative model of metabolites, equol, and heart disease
This grant looks at how a person’s body processes soy isoflavones into equol and how that relates to atherosclerotic heart disease, using complex data to build predictive models.
-
Lp(a) and HIV: Understanding Heart Disease Risk in HIV Patients
This program looks at how Lipoprotein(a) contributes to higher heart disease risk in people with HIV and what Lp(a) levels mean for future treatments.
-
PVAT and arteries: why some vessels resist plaque
Aims to understand how fat tissue around arteries influences atherosclerosis, especially why the left internal mammary artery stays healthy while others don’t.
-
Understanding why some artery plaques become dangerous using genetics, tissue maps, and advanced imaging
Researchers will combine human genetic data with single-cell and spatial tissue maps to find why certain atherosclerotic plaques are more likely to cause heart events, aiming to improve prediction and prevention.
-
Opportunistic heart risk detection from abdominal CTs using robust AI
A doctor-scientist team at Stanford will use existing abdominal CT scans and medical records to build a trustworthy AI tool that helps predict future heart problems in adults.
-
Extracellular Vesicles as Clues and Targets for Heart Disease in People with HIV
This grant investigates how tiny particles in the blood, called extracellular vesicles, relate to heart disease risk in people living with HIV and looks for new ways to prevent or treat it.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.